Sign in

    Jenna Li • Jefferies

    Jenna Li is a Vice President in Investment Banking at Jefferies, specializing in capital markets transactions and advisory services. While her specific company coverage, performance metrics, and investment track record are not publicly detailed, she holds a leadership role within the firm based in New York. Jenna joined Jefferies after developing her expertise in financial analysis and strategic consulting, contributing to key investment banking projects for the firm’s global client base. Her professional credentials and securities licensing status are not specified in the available records.

    Jenna Li's questions to ADC Therapeutics SA (ADCT) leadership

    Jenna Li's questions to ADC Therapeutics SA (ADCT) leadership • Q2 2025

    Question

    Jenna Li from Jefferies, on behalf of Kelly Hsu, asked about the expected durability of the high complete response rates observed in the LOTUS-5 and LOTUS-7 trials. She sought clarity on the potential incremental durability benefit versus glufitamab monotherapy and what early durability metrics might be shared in the next LOTUS-7 update.

    Answer

    Chief Medical Officer Mohamed Zaki explained that high complete response (CR) rates are a strong surrogate for durability and noted that 25 of 26 CR patients in LOTUS-7 remained in response at the data cutoff. He mentioned both ZYNLONTA and glufitamab have shown significant durability as single agents. CEO Ameet Mallik added that future data updates will include updated Swimmer's plots and, as data matures, metrics on the median duration of CR at six and twelve months.

    Ask Fintool Equity Research AI

    Jenna Li's questions to Invivyd Inc (IVVD) leadership

    Jenna Li's questions to Invivyd Inc (IVVD) leadership • Q1 2024

    Question

    Speaking on behalf of Michael Yee, the analyst asked for specific details on the early launch, including the magnitude of orders, shipment status, and the timing for booking sales.

    Answer

    The company declined to provide specific early launch metrics, stating that it is too early to provide data that would be informative for the full year. They noted they are encouraged by what they are seeing and will provide more detailed updates on sales and trends as the launch progresses, likely in the summer or fall.

    Ask Fintool Equity Research AI

    Jenna Li's questions to Invivyd Inc (IVVD) leadership • Q1 2024

    Question

    Jenna Li, on behalf of Michael Yee at Jefferies, asked about the magnitude of PEMGARDA orders, shipment status, and the timing for booking sales.

    Answer

    Marc Elia, Chairman, stated that while the company is encouraged by early launch progress, it is too early to provide specific details on order volumes or sales trends. He indicated that more informative updates would be provided in the summer and fall as the launch matures.

    Ask Fintool Equity Research AI